Biocon biosimilar plant criticized again by the FDA

Biocon research lab
Biocon research lab (Biocon)

The plant in India where Biocon makes the biosimilars it shares with Mylan was given a clean bill of health by the FDA last year—but not for long. The FDA posted a new Form 483 for the facility Tuesday following an inspection last month.

The most recent citation of the Bangalore plant includes only two observations, unlike in 2017 when a long list of problems led the FDA to delay approvals of the biosimilars that Mylan and Biocon were developing. The two notations, however, again spotlighted places where Biocon needs to tighten up its processes to prevent contamination of sterile drugs.

Biocon last month acknowledged the two observations and said they were part of a pre-approval inspection of a new injectables line at the plant. A separate inspection of a solid dose facility resulted in no observations. A Biocon spokesperson said in an email that the company has addressed the findings and responded to the regulator. She said Biocon remains committed to quality.    

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Specifically, the FDA faulted plant employees for not carefully sanitizing and inspecting its restricted-access barrier systems. The FDA didn’t like the way the plant was tracking rejected vials. Inspectors also said investigations into unexplained discrepancies didn’t always include all of the tests the FDA thought should be conducted.

When the plant ran into FDA concerns in 2017 during a preapproval inspection, Biocon initially downplayed what turned out to be an 8-page, 10-observation critique that found problems across the entire range of processes, including in aseptic processing and filling, environmental monitoring, data recording, cleaning procedures, and even in its processes for buying sterile gloves for employees. It took about 6 months for Biocon to get those issues resolved, and the efforts delayed approval of the partners’ Herceptin biosimilar by three months.

RELATED: FDA slams Biocon sterile plant where Herceptin biosimilar is to be produced

Last June, the Indian company reported to the stock exchange in India that the FDA had issued an Establishment Inspection Report for the plant, clearing that inspection. Last year, the Indian drugmaker also struck a partnership with Novartis to produce “next generation” biosimilars.

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.